News

Ambulatory Encounters for Hematology/Oncology Unchanged Since 2007


 

Hematologist/oncologists in group practice had a median of 2,719 ambulatory encounters in 2010, up just 0.3% since 2007, according to a survey by the Medical Group Management Association.

Hematologist/oncologists in hospital-owned practices averaged 2,362 ambulatory encounters in 2010, compared with 2,864 for those who were not in hospital-owned practices, the MGMA reported. Male hematologist/oncologists had a median of 2,864 ambulatory encounters, while the median for females was 2,240. Geographically speaking, those in the western United States had the highest number of ambulatory encounters, 3,027, while those in East, with 2,295 encounters, had the lowest.

The MGMA considered an ambulatory encounter to be "documented, face-to-face contact between a patient and a provider" that did not take place in an inpatient hospital and did not involve a surgical procedure.

The 2010 edition of the annual survey, conducted among MGMA members and nonmembers, includes data from 2,846 group practices representing 59,375 physician and nonphysician providers. The MGMA presents survey highlights in its In Practice blog.

Recommended Reading

Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
MDedge Hematology and Oncology
Biomarker Predicts Worse Outcome in Chronic Myeloid Leukemia
MDedge Hematology and Oncology
No Increased Acute Myeloid Leukemia Risk in First-Degree Relatives
MDedge Hematology and Oncology
Blinatumomab Shows BiTE in Relapsed/Refractory ALL
MDedge Hematology and Oncology
Paraneoplastic Autoimmune Multiorgan Syndrome Proves Rapidly Fatal
MDedge Hematology and Oncology
Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies
MDedge Hematology and Oncology
FDA: Increased PAH Risk Seen With Dasatinib
MDedge Hematology and Oncology
Personalized medicine: myth to reality
MDedge Hematology and Oncology
CD19-redirected T cells induce remission in CLL patients
MDedge Hematology and Oncology
Brd4: Potential new target in AML
MDedge Hematology and Oncology